The promise of prostate-specific membrane antigen (PSMA)–targeted radionuclide therapy
is being demonstrated by a growing number of reports detailing institutional experience with …

At present, prostate cancer remains the second most occurring cancer in men, in Europe.
Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration …

Since the first clinical use of 131I-labeled prostate-specific membrane antigen (PSMA)(1),
xerostomia has been identified as a relevant side effect of PSMA radioligand therapies …

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is highly
expressed on prostate adenocarcinomas, exhibits only limited expression in benign and …

Purpose: PSMA-targeted radioligand therapy (PRLT) is a promising treatment option for
patients with metastatic castration-resistant prostate cancer (mCRPC). However, a high …

Simple Summary A significant number of prostate cancer patients will progress to metastatic
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …

Prostate specific membrane antigen (PSMA) is a transmembrane protein that is highly
expressed on prostate epithelial cells and is strongly upregulated in prostate cancer …

Prostate specific membrane antigen (PSMA) has become a major focus point in the research
and development of prostate cancer (PCa) imaging and therapeutic strategies using …

In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …

Despite significant advances in therapeutic developments for prostate cancer over the last 2
decades, metastatic prostate cancer remains a lethal disease. Prostate-specific membrane …